Sort   by:  
 Page size 
Proteomicsthe landscape of phosphorylated HLA-I ligands
The identification and prediction of HLA-I–peptide interactions play an important role in our understanding of antigen recognition in infected or malignant cells. In cancer, non-self HLA-I ligands can arise from many different alterations, including non-synonymous mutations, gene fusion, cancer-spec...
ORGANISM(S): Homo sapiens (Human) 
2019-12-18 | PXD013831 | Pride
Immunopeptidomics Hla binding peptides Phosphorylations 
ProteomicsPre-fractionation extends, but creates a bias in the detectable HLA class Ι ligandome
HLA class Ι molecules on the cell surface enable CD8+ T lymphocytes to recognize cellular alterations in the form of antigens, including mutations, protein copy number alterations, aberrant post-translational modifications or pathogen proteins. At any given moment, tens of thousands of different sel...
ORGANISM(S): Homo sapiens (Human) 
2019-02-25 | PXD011257 | Pride
Hla class ι ligandome  hla class ι peptide ligands  high ph reversed phase  strong cation exchange  pre-fractionation 
ProteomicsImmunogenicity of non-canonical HLA-I tumor ligands identified through proteogenomics
Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from non-canonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the presentation and immunogenicity of nonC antigens across different cancer types to bett...
ORGANISM(S): Homo sapiens (Human) 
2023-02-03 | PXD036856 | Pride
Human Non-canonical hla-i ligands 
ProteomicsNaturally processed flucloxacillin haptenated HLA ligands
This study has demonstrated that natural flucloxacillin haptenated HLA-B*57:01 ligands arepresented by antigen presenting cells through multiple pathways. Identification of such epitopes will help to define the chemical signals responsible for drug-induced immunological disease.
ORGANISM(S): Homo sapiens (Human) 
2020-08-05 | PXD020137 | Pride
Dili Hla-b*57:01 Drug hypersensitivity Flucloxacillin 
ProteomicsCharacterization of the HLA class I Ligandome from Extracellular vesicles
Extracellular vesicles have shown promise in the field of anti-tumor vaccines. EVs are antigen-presenting entities capable of eliciting potent T-cell responses and have therefore being explored as cell-free based peptide vaccine vectors. However, whether the EV ligandome sufficiently resembles the c...
ORGANISM(S): Homo sapiens (Human) 
2021-07-05 | PXD021177 | Pride
Ev vaccines Extracellular vesicles Immunopeptidomics Ligandome Hla-i 
ProteomicsThe HLA-Ligand-Atlas. A resource of natural HLA ligands presented on benign tissues
The human leukocyte antigen (HLA) complex regulates the adaptive immune response by showcasing the intracellular and extracellular protein content to the immune system. T cells recognize these HLA-presented peptides as self or foreign and can elicit an immune response. In this work, we describe the...
ORGANISM(S): Homo sapiens (Human) 
2021-04-16 | PXD019643 | Pride
Human Hla Benign tissues Immunopeptidomics 
ProteomicsMHC peptides presentation is limited by availability of empty HLA molecules rather than the supply of peptides ligands
Whether the presentation levels of the major histocompatibility complex (MHC, called the human leukocytes antigens, HLA, in humans) is limited by the availability of peptide ligands for loading or by the supply of empty MHC molecules, is a yet unresolved issue. This study aims to tackle this dilemma...
ORGANISM(S): Homo sapiens (Human) 
2018-05-10 | PXD007596 | Pride
Interferon Mhc Peptidome Immunopeptidome Hla 
ProteomicsNaturally presented benzypenicillin-modified HLA-A*02:01 ligands
This study characterised the array of benzylpenicillin-modified ligands within the immunopeptidome of HLA-A*02:01. We further describe a novel target of penicillin within the immunopeptidome and proteome. Identification of penicillin-modified ligands within the immunopeptidome will allow future immu...
ORGANISM(S): Homo sapiens (Human) 
2025-10-01 | PXD057177 | Pride
Antibiotics Penicillin Hla 
ProteomicsLow-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Potential Targets for Cancer Immunotherapy
Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) lead to cell-cycle arrest but also trigger T cell-mediated immunity, which might be mediated by the qualitative and quantitative changes in human leukocyte antigen (HLA) ligands on the cancer cell surface. We investigated the effects of CDK4/6i, Abema...
ORGANISM(S): Homo sapiens (Human) 
2021-09-10 | PXD024965 | Pride
Abemaciclib Palbociclib Breast cancer Cdk4/6 inhibition Mhc ligand 
ProteomicsThe HLA-Ligand-Atlas. A resource of natural HLA ligands presented on benign tissues
A use case of the benign HLA-Ligand-Atlas is the prioritization of tumor-associated targets for e.g. peptide vaccination. Based on three glioblastoma samples, we illustrated how many of these peptides are covered in the benign dataset. The experimental and computational workflow for the isolation an...
ORGANISM(S): Homo sapiens (Human) 
2021-04-16 | PXD020186 | Pride
Human Hla Glioblastoma Immunopeptidomics 
Sort   by:  
 Page size